Working… Menu

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03745287
Recruitment Status : Recruiting
First Posted : November 19, 2018
Last Update Posted : January 22, 2021
CRISPR Therapeutics
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated